Today’s good news story comes from the good news network.

Picture a very unhappy situation: you have leukemia; what are your options? Everyone knows about the side effects of chemo, and most people will have some idea about the Nobel Prize-winning CAR-T cell therapy—but there’s also a third option.

It seems startling to be so overlooked because it’s so straightforward. Blinatumomab cured the young fellow above of his B-cell acute lymphoblastic leukemia.

The BBC reports that 20 medical centers in the UK are already using off-brand stocks of blinatumomab to treat this cancer, and the country has already approved the drug for adult use.

‘Blina,’ as it’s referred to for short, is also an immunotherapy drug; it seeks out and kills cancer cells that typically disguise themselves from the body’s innate immune system. However, unlike chimeric antigen receptor T cells (CAR-T cell), blina is cheaper.

Blina is a kind of targeted therapy drug called a bispecific T-cell engager (BiTE). It’s administered via a pump and plastic bag through a tube inserted into the patient’s arm.

The bag is carried around in a slim backpack, and the supply lasts a few days. CAR-T cell therapy requires a patient’s cells to be taken out and modified to fight off whichever cancer is present—which takes time.

Like CAR-T, the healthy normal cells are not destroyed as in the case of chemotherapy, allowing the patient to continue leading a mostly normal life.

“Chemotherapies are poisons that kill the leukemic cells but also kill and damage normal cells—and that is what causes their side effects,” said chief investigator and consultant pediatric hematologist Professor Ajay Vora to the BBC. “Blinatumomab is a gentler, kinder treatment.”

Gentler on the body—not on the cancer. Arthur, now 11, was one of the first kids to receive the treatment at Great Ormond Street Hospital in London. His family got the word that his blood cancer was cured on New Year’s Eve.

Having started chemo years before, which both left him very weak and failed to kill the cancer, the family called Blina a “little ray of sunshine” and said that they celebrated the new year twice as hard.

On March 29th, 2018, the US Food and Drug Administration granted accelerated approval to blinatumomab after successful trial results, though serious side effects were not uncommon. It’s available for B-cell acute lymphoblastic leukemia treatment.

The good news in this article is Cancer is still under attack, and new discoveries are making survival much more frequent. Today’s JohnKu talks about science. I hope you have a great weekend.

Discoveries by John W. Howell © 2024

The disease still kills,

But science still plods along . . .

Miracle life saves.

Today’s good news story comes from the Epoch Times. This story was sent to me by Noelle Granger. Thanks, Noelle. I have edited it slightly for length.

A picture designed by The Epoch Times using imagery from Nancy Feighan and Molly Shannon/Shutterstock.

‘I Don’t Ask for Anything’: Man, 81, Clears Snow From Neighborhood Sidewalks for Over 20 Years

An 81-year-old who has been clearing snowy sidewalks in his neighborhood for over 20 years refuses to accept cash donations, insisting he loves the snow and helping his neighbors.

Jimmie Sinatra grew up in Lakewood, Ohio, and bought a house with his wife in the area in 1995. That same year, he invested in his first snowblower. Soon, he upgraded to a Craftsman snowblower that he can walk behind and has been maintaining the prized apparatus ever since.

“I just like snow,” Mr. Sinatra told The Epoch Times. “I love playing in the snow, walking, and taking my dog for a walk in the snow, and I decided to do a couple of neighbors’ sidewalks. Then, when my wife and I talked about getting a bigger snowblower, I decided to go all the way up the block.”

Currently, Mr. Sinatra clears snow from about 34 sidewalks, and if there happens to be a school at the end of each block, he helps there, too, as he hates seeing kids walking in the snow.

Mr. Sinatra clears the streets when the snow reaches 5 or 6 inches deep. Initially, only his immediate neighbors knew that he was helping clear snow for the neighborhood, and those living further down the street had no idea about it. However, over the years, a couple of people have noticed his handiwork and have asked if he could clear their driveways, too.

“I don’t ask for money, I don’t ask for anything, I just do it to help the neighbors,” Mr. Sinatra said. “It’s something for me to do. I enjoy it, that’s all. I enjoy helping people.”

Before retiring in July 1998, Mr. Sinatra worked in the material handling department of the Ford Motor Company in Burke, Ohio, for 33 years. His beloved wife encouraged his snowblowing hobby until she passed away four years ago from Lou Gehrig’s disease.

“That’s the way she was too, helping our neighbors out,” said Mr. Sinatra, who has become a religious man since his wife fell ill. “I changed my ways and just prayed every day and every night,” he said. “I think I used to take everything for granted, but I don’t anymore because it’s all in God’s hands. … I know my wife’s spirit is in the house with me, and that’s what I live for.”

At the age of 81, Mr. Sinatra has his own health problems. In May 2023, he was diagnosed with stage four chronic obstructive pulmonary disease (COPD) and emphysema in both lungs. He has trouble breathing so he wears a scarf to keep warm and carries an inhaler when he leaves the house to clear snow.

And, when he can no longer continue, he hopes that someone will take over and continue to clear the snow on the sidewalks and driveways of people who can’t do it.

“I have a lot of nice neighbors, and they take care of me and watch out for me, check up on me and make sure I’m okay because I’m by myself now,” said Mr. Sinatra, imploring: “If you see somebody that needs help, no matter what it is, give them a helping hand and don’t be afraid to do it. Just help your neighbors and your fellow man out.”

The good news in this story is one man took it upon himself to help his neighbors for the joy of doing so. Today’s JohnKu talks about joy. I hope you have a wonderful weekend.

Helping by John W. Howell

No one has to ask,

It is just the absolute . . .

Today’s good news comes from station KDFW, which serves Dallas and Fort Worth, Texas.

Screengrab of Eban Barns from FoxNews 4

Royse City Boy Scout builds doghouses for Dallas Animal Services

by Lori Brown

ROYSE CITY, Texas – An eighth-grade Boy Scout from Royse City is working toward the prestigious Eagle rank by helping save the dogs’ lives in Dallas.

He built and delivered 20 dog houses to Dallas Animal Services this week to be given out to families in need.

“I really enjoy being around dogs, and I found out that they can be removed from their homes because they don’t have a shelter,” he said. “So I wanted to do a project for that so that dogs wouldn’t be removed.”

Eben reached out to Det. Michael Bono with the Dallas Police Department’s animal cruelty unit to find out how he could help animals in a city that is struggling with shelter overcrowding.

“One of our biggest challenges we have in the animal cruelty unit is individuals that don’t provide a means of shelter,” Bono said. “Whether it’s they just don’t have the means to do so, or they choose not to. But animals in North Texas are at risk based on not having shelter.”

Eben researched how to build a doghouse, but that had its challenges. His prototype broke after the first try. He contacted businesses to collect donations for the supplies he needed.

Eben’s mom, Brooke Barnes, said she was proud of his perseverance.

“He sets a goal and sticks to it,” she said. “So to see him build the prototype, see him get everything organized, and then to see him oversee the work day and the delivery of the doghouses yesterday, it was really exciting.”

And now it’s 20 dogs that will soon have the excitement of their own.

“We’ve seen animals come in because the families just couldn’t provide,” Bono said. “And I think through Evan’s Eagle Scout project, he’s able to help 20 of those families.”

The hope is others will be inspired to follow Eben’s lead.

“I think Eben really nailed this project. I think the doghouses turned out excellent. I think it’s the tip of the iceberg,” Bono said. “I think a lot of other scouts and individuals could do this, and it could greatly impact the greater Dallas and North Texas area.

Eben has now completed all of the requirements to become an Eagle Scout. The next step is his board of review to verify his work.

The good news here is a young man saw a need and did what was necessary to satisfy that need. Today’s JohnKu talks about action. I hope you have a wonderful weekend.

Need by John W. Howell © 2023

There’s a difference,

Between just seeing a need . . .

And action to solve.

Today’s good news comes from the Good News Network.

It’s not referring to a tropical disease to say that someone has an EGOT. It means they’ve got a mantlepiece at home where stand an Emmy, a Grammy, an Oscar, and a Tony—the four major pop culture awards in America.

Only 18 entertainers have achieved this quadruple, and now Elton John stands among them as the 19th, having recently won an Emmy for his concert film, Elton John Live: Farewell From Dodger Stadium.

John was not able to attend the ceremony because of needed recovery from knee surgery, “which isn’t surprising if you think of the number of pianos he’s jumped off from in platform heels,” said John’s husband, David Furnish.

John has collected two Oscars: one for The Lion King’s Can You Feel The Love Tonight? and another for Rocketman’s (I’m Gonna) Love Me Again. 

For the ‘T’ in EGOT, he won a Tony for scoring the musical version of the opera Aida. 

For the ‘G’—the Grammy, it’s a case of take your pick, with John having collected quite a few over his decades as a musician.

“I am incredibly humbled to be joining the unbelievably talented group of EGOT winners tonight,” said John in a statement. “The journey to this moment has been filled with passion, dedication, and the unwavering support of my fans all around the world. Tonight is a testament to the power of the arts and the joy that it brings to all our lives. Thank you to everyone who has supported me throughout my career; I am incredibly grateful.”

According to Smithsonian Magazine, the term EGOT was first used on Miami Vice. Its imaginary alumni include Richard Rogers, Hellen Hayes, Rita Moreno, Whoopi Goldberg, Viola Davis, John Legend, Alan Menken, Mell Brooks, Audrey Hepburn, John Gielgud, Marvin Hamlisch, Johnathan Tunic, Mike Nichols, Scott Rudin, Robert Lobez, Andrew Lloyd Weber, Tim Rice, and Jennifer Hudson.

It seems appropriate that the acronym would be finished on Elton’s final show ever on tour in North America, the curtain call of all curtain calls, and a tremendous achievement to mark the end of a long chapter in a tremendous career.

WATCH Tiny Fey and Amy Pohler present the award along with peers…

The good news in this story is that a man who has invested his life and energy into entertainment has been recognized for his achievement and hard work. Today’s JohnKu talks about recognition. I hope you have a wonderful week.

Others by John W. Howell © 2023

When something is great,

And is done by someone else . . .

Do you offer praise?

Today’s good news story comes from the Good News Network.

Long-Lost ‘Legend’–Leopard Barbel Fish Found Again in Turkey’s Dammed-up Rivers

A team of ichthyologists (zoologists who study fishes) in Türkiye (Turkey) has rediscovered a “legend” in the form of a carp-like, spotted fish called the leopard barbel (Luciobarbus subquincunciatus) in the Turkish section of the Tigris River.

The leopard barbel was once abundant, ranging from Eastern Türkiye, Eastern Syria, Iran, and Iraq in the Tigris-Euphrates river system. Over the last three decades, however, fishing, pollution, habitat destruction, and dam construction have pushed the species to the edge of extinction and was last scientifically documented in 2011.

However, anecdotal evidence from local fishers suggested that the fish may have still been out there, so Associate Professor Cüneyt Kaya and Assistant Professor Münevver Oral at Recep Tayyip Erdogan University enlisted their help to find one.

“There is nothing quite like the feeling of finding that a species that has been pushed to the brink of extinction is still hanging on, despite the odds,” said Kaya upon their success. “It is even more thrilling than discovering a new species because it means that we can give a rare species a second chance.

The team started by looking at the scientific literature about where the species had been previously found. However, those data were collected before nine dams were built in the Turkish portion of the Tigris River.

The dams alter water flow regimes, and cold water accumulating at the reservoirs’ bottom is sometimes released downstream. The release of cold water drives many freshwater fish toward warmer waters, so the team had to adjust its strategy to look further downstream from the dams.

Just days after the second of two expeditions, Kaya and Oral got a video call from local fisherman Mehmet Ülkü. He had caught a 20-inch (50 centimeter), 4.4-pound (2-kilogram) fish with conspicuous black spots and the telltale fleshy filament that dangles from the mouths of this type of freshwater fish.

Ülkü kept the fish alive overnight in a tank with a constant oxygen supply. At the same time, Kaya took a direct flight to the region and then drove nearly six hours to Cizre in the far southeastern reaches of Turkish Kurdistan, where the species was found, while Oral drove more than 11 hours through the night to see the fish and confirm its identity.

By the time they arrived, Ülkü had caught a second leopard barbel safely in his nets, and they were able to help him release the first one as well.

“We dropped everything and would have gone to the ends of the Earth to see this fish, this legend, alive in the wild,” Oral said. “I have never seen a fish as beautiful as this. It was the realization not only of our dream to find this lost species but of the hope that not all is lost—we still have a chance to protect the leopard barbel and all of the other incredible freshwater species it shares its home with.”

After Kaya and Oral took photos and measured the size and shape of the two fish, they were joined by the local Cizre fisheries aquaculture department to release the fish safely, which they described as a joyous event.

“We all have a role to play in protecting our incredible natural heritage, and I am proud to have used my skills to help rediscover the leopard barbel,” Ülkü, the fisherman, said. “Safeguarding this species into the future will require educating other fishers and bringing scientific knowledge and local expertise together.”

Kaya and Oral plan to conduct a series of seminars for fishers and teachers to help build pride in their riverways and wildlife, using the rediscovery as a case study to protect the Tigris River and its rich biodiversity. They are also hoping to better understand how many leopard barbel might still exist and where they are still found across their historic range.

The expedition to confirm the leopard barbel still exists was co-funded by Re:wild, the world leaders rediscovering and protecting lost species. The fish is the second on Re:wild and SHOAL’s Most Wanted Lost Fishes list to be rediscovered. The first, the Batman River loach, was found by the same intrepid team in Southeastern Türkiye in late 2021.

The good news in this situation is that in spite of human negligence, a species fights hard and survives. Today’s JohnKu talks about the ability of animals to survive. I hope you have a beautiful weekend.

Nature by John W. Howell © 2023

In spite of humans,

Species fight hard to survive . . .

Nature can be tough.

Today’s Good News comes from the Good News Network. Here it is in its entirety.

A collaborative study involving experts in Europe and the US found the treatment of stem cells appears to protect the brains of MS patients from further damage.

In the first-ever clinical trials in humans, the researchers found patients injected with the stem cells exhibited no increase in disability or worsening of symptoms.

The promising study, published in the journal Cell Stem Cell, is hoped to lead to further clinical trials that could provide treatment for progressive MS.

More than two million people live with MS across the globe, and while some treatments currently available can reduce the severity and frequency of relapses, two-thirds of patients still transition into a debilitating secondary progressive phase of the disease within 25 to 30 years of diagnosis.

An autoimmune disorder like Lupus, ALS, and Crohn’s, MS is characterized by the body’s immune system attacking and damaging myelin—the protective sheath of tissue around nerve fibers, disrupting messages sent around the brain and spinal cord.

An immune cell called a microglial can attack the central nervous system in progressive forms of MS, causing chronic inflammation and damage to nerve cells.

Recent scientific advances involving the transplantation of stem cells have raised expectations that therapies could be developed to help ameliorate this damage.

Previous experiments in mice from the Cambridge University unit of the new study team have shown that skin cells reprogrammed to be brain stem cells and transplanted into the nervous system can help to reduce inflammation and may even be able to help repair damage caused by MS.

The research team behind the latest study, incorporating experts from the UK, US, Switzerland, and Italy, completed a world-first early-stage clinical trial in which neural stem cells were injected into the brains of 15 patients with secondary MS recruited from two Italian hospitals.

Along with the Cambridge unit, teams performed the trials at the University of Milano-Bicocca, the Casa Sollievo della Sofferenza and Santa Maria Terni hospitals in Italy, the Ente Ospedaliero Cantonale hospital in Lugano, Switzerland, and the University of Colorado in the United States.

The transplant patients were followed for 12 months. No deaths or serious adverse events related to the treatment were observed throughout the year. Side effects were mild, transient, and reversible.

All patients had a high degree of disability at the start of the clinical trial—for example, they were wheelchair-bound—but during the 12-month observation period, they showed no increase in disability or worsening of symptoms. None of the patients showed symptoms that would indicate a relapse or signs of clinical progression, suggesting substantial stability of the pathology.

A subgroup of patients was also assessed for changes in the volume of brain tissue associated with disease progression, which found that the larger the dose of injected stem cells, the smaller the reduction in this brain volume over time.

The researchers speculate that this may be down to the stem cell transplant dampening inflammation.

Professor Stefano Pluchino, a co-leader of the study from the University of Cambridge, admitted that though the research had limitations, the findings were extremely promising.

“We desperately need to develop new treatments for secondary progressive MS, and I am cautiously very excited about our findings, which are a step towards developing a cell therapy for treating MS,” he said.

“We recognize that our study has limitations: it was only a small study, and there may have been confounding effects from the immunosuppressant drugs, for example, but the fact that our treatment was safe and that its effects lasted over the 12 months of the trial means that we can proceed to the next stage of clinical trials.”

Professor Angelo Vescovi, another co-leader of the study from the University of Milano-Bicocca, added that it has taken nearly three decades to translate the discovery of brain stem cells into this experiment, which he said will “pave the way” to broader studies “soon to come.”

The Good News is that the scientific community is still working on improving life. Today’s JohnKu talks about perspective in a bad news world. I hope you have a wonderful weekend.

Good News by John W. Howell © 2023

The media thinks,

All we want is the horrific . . .

How wrong can they be?